Case report highlights severe thrombocytopenia in an AIDS patient due to trimethoprim-sulfamethoxazole, suggesting significant risks.
We report the case of a 55‐year‐old male with AIDS who developed severe thrombocytopenia following initiation of trimethoprim–sulfamethoxazole. Despite drug discontinuation and supportive measures, thrombocytopenia persisted, leading to the patient’s death. This case highlights the complexities of drug‐induced immune thrombocytopenia in immunocompromised patients and emphasizes the risks associated with trimethoprim–sulfamethoxazole.
No takes yet. Share an insight, caveat, or question.
Cimperman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: